Navigation Links
Human Genome Sciences Advances Oncology Portfolio
Date:4/16/2008

ombination with Velcade

(bortezomib) in advanced multiple myeloma, and expects to have data

available in the third quarter of 2008.

-- In December 2007, HGS initiated dosing of approximately 105 patients in

a randomized Phase 2 trial of HGS-ETR1 in combination with paclitaxel

and carboplatin as first-line therapy in advanced non-small cell lung

cancer, and expects to have data available in 2009.

-- Today, HGS announced that it plans by mid-2008 to initiate a randomized

Phase 2 trial of HGS-ETR1 in combination with Nexavar (sorafenib) in

hepatocellular cancer. The study in hepatocellular cancer will begin

with a safety lead-in to assure the safety of this combination therapy

in patients with hepatocellular cancer who are infected with hepatitis

C.

About the HGS IAP Inhibitor Program

In December 2007, the HGS oncology portfolio was further strengthened by a licensing and collaboration agreement between HGS and Aegera Therapeutics Inc. This agreement provides HGS with exclusive worldwide rights (excluding Japan) to develop and commercialize HGS1029 (formerly AEG40826) and other small- molecule inhibitors of IAP (inhibitor of apoptosis) proteins in oncology. Preclinical studies of HGS1029 in combination with the Company's TRAIL receptor antibodies demonstrated dramatic synergistic activity against a number of cancer types. HGS1029 has also shown significant anti-tumor activity alone and in combination with other agents in a broad range of cancers. HGS expects to initiate a Phase 1 clinical trial of HGS1029 by mid-2008 and plans to develop its TRAIL receptor antibodies and IAP inhibitors in combination with one another and in combination with other therapeutic agents.

About HGS-ETR1 and HGS-ETR2

HGS-ETR1 and HGS-ETR2 are agonistic human monoclonal antibodies that directly induce cancer-cell death by specifically binding to and activating th
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... AZ (PRWEB) July 30, 2014 Sales ... the launch of blended sales training programs for companies ... sales training programs used by thousands of salespeople over ... blended sales training program can be customized to address ... , The blended sales training program consists ...
(Date:7/30/2014)... 2014 Vycom announces the addition of ... to meet Factory Mutual (FM) 4910 fire propagation and ... wet benches, process tools, fume hoods, furniture and cabinetry. ... to semiconductor wafers used in electronic chip manufacturing. ... solution with excellent workability and superior aesthetics. It is ...
(Date:7/30/2014)... DIEGO , July 30, 2014   Epic ... designs and develops novel diagnostics to personalize and advance ... appoint of Gregory T. Lucier as chairman ... chairman and CEO of Life Technologies (formerly Invitrogen). Mr. ... as Epic commercializes its circulating rare cell analysis platform ...
(Date:7/30/2014)... Vala Sciences was recently awarded ... Agency (EPA). This new contract was awarded for ... tests designed to assess the effect of chemical ... connections between neurons (synapses), which are critical for ... by environmental pollutants likely contributes to a variety ...
Breaking Biology Technology:Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3
... FREMONT, Calif., Aug. 13 WaferGen Biosystems,Inc. (OTC ... expression, genotyping, cell biology and stem cell research ... and,announced financial results for the quarter and six ... Developments and Milestones:, -- Initiation of alpha ...
... MS, EDMONTON, Aug. 12 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), today,announced financial and ... 2008. BioMS Medical, in partnership with Eli Lilly ... for the treatment of MS,undergoing pivotal trials in ...
... Calif., Aug. 12 ChromaDex,Corporation, (OTC Bulletin Board: ... research, today announced financial results for the,second quarter ... accordance with,U.S. Generally Accepted Accounting Principles (GAAP), ChromaDex ... $0.03 per share for the,three months ended June ...
Cached Biology Technology:WaferGen Announces Second Quarter 2008 Financial Results 2WaferGen Announces Second Quarter 2008 Financial Results 3WaferGen Announces Second Quarter 2008 Financial Results 4WaferGen Announces Second Quarter 2008 Financial Results 5WaferGen Announces Second Quarter 2008 Financial Results 6WaferGen Announces Second Quarter 2008 Financial Results 7WaferGen Announces Second Quarter 2008 Financial Results 8BioMS Medical Announces Second Quarter 2008 Results 2BioMS Medical Announces Second Quarter 2008 Results 3BioMS Medical Announces Second Quarter 2008 Results 4BioMS Medical Announces Second Quarter 2008 Results 5ChromaDex Announces Second Quarter 2008 Financial Results 2ChromaDex Announces Second Quarter 2008 Financial Results 3
(Date:7/30/2014)... DCToday scientists unveiled the first high-resolution map of ... entire country of Per. The new and improved ... sea change for future market-based carbon economies. ... high ecological diversity and it provides the critical ... for conservation, land use, and enforcement purposes. The ...
(Date:7/29/2014)... of Bristol,s Nutrition and Behaviour Unit (NBU) has looked ... planning meals. , The research, to be presented at ... (SSIB 2014) in Seattle, USA this week [29 July ... team was led by Professor Jeff Brunstrom, and is ... part of a Biotechnology and Biological Sciences Research Council ...
(Date:7/29/2014)... climate warms and sea ice retreats, the North is ... increasingly open water which is predicted to extend across ... century. Storms thus have the potential to create Arctic ... and unpredictable element to the region. , A University of ... the middle of the Arctic Ocean, and detected house-sized ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3Huge waves measured for first time in Arctic Ocean 2Huge waves measured for first time in Arctic Ocean 3
... Wake Forest University Baptist Medical Center and three ... activates the spores in anthrax, the deadly bacterial ... "A key aspect of anthrax spore biology concerns ... becomes a reproductive, disease-causing bacterium," explained Al Claiborne, ...
... Software (IOS) today,announced the release of GeneLinker(TM) ... award-winning Gene Expression and Proteomics Analysis,Software products.,"The ... and analyzing,protein biomarker data, a high priority ... have integrated the Protein Biomarker Package into ...
... deliver the hoped-for knockout punch breakthrough against the defences ... antibiotic resistance. , Techniques such as genomic sequencing and ... of new antibiotic compounds easier and more productive. But ... upper hand ?and if three billion years of bacterial ...
Cached Biology News:Scientists seek answers on what activates deadly anthrax spores 2Improved Outcomes Releases GeneLinker(TM) Gold and Platinum Version 4.6 2Improved Outcomes Releases GeneLinker(TM) Gold and Platinum Version 4.6 3Learning to fight an adversary that won't stay down 2
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
muscle actin (HUC1-1)...
FluoSpheres® biotin-labeled microspheres, 0.2 µm, yellow-green fluorescent (505/515) *1% solids*...
KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
Biology Products: